Patents by Inventor Jeremy I. Levin

Jeremy I. Levin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
    Publication number: 20020147342
    Abstract: Compounds of the formula 1
    Type: Application
    Filed: November 13, 2001
    Publication date: October 10, 2002
    Applicant: American Cyanamid Company
    Inventors: Jeremy I. Levin, Aranapakam M. Venkatesan, Derek C. Cole, James M. Chen, Jamie M. Davis, George T. Grosu
  • Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
    Publication number: 20020132826
    Abstract: This invention provides, low molecular weight, non-peptide inhibitors of matrix metalloproteinases and TNF-&agr; converting enzyme (TACE, tumor necrosis factor-&agr; converting enzyme) of formula:
    Type: Application
    Filed: December 11, 2000
    Publication date: September 19, 2002
    Inventors: Jeremy I. Levin, Arie Zask, Yansong Gu, Jay D. Albright, Xuemei Du
  • Acetylenic sulfonamide thiol TACE inhibitors
    Publication number: 20020103163
    Abstract: The present invention relates to acetylenic aryl sulfonamide thiols which act as inhibitors of TNF-&agr; converting enzyme (TACE). The compounds of the present invention are useful in disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.
    Type: Application
    Filed: August 30, 2001
    Publication date: August 1, 2002
    Applicant: American Cyanamid Company
    Inventors: Jeremy I. Levin, James M. Chen
  • Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
    Publication number: 20020086890
    Abstract: Compounds of the formula: 1
    Type: Application
    Filed: December 21, 2001
    Publication date: July 4, 2002
    Applicant: American Cyanamid Company
    Inventors: Jeremy I. Levin, Aranapakam M. Venkatesan, James M. Chen, Arie Zask, Vincent P. Sandanayaka, Mila T. Du, Jannie L. Baker
  • Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
    Patent number: 6358980
    Abstract: Compounds of the formula: useful in the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: March 19, 2002
    Assignee: American Cyanamid Company
    Inventors: Jeremy I. Levin, Aranapakam M. Venkatesan, James M. Chen, Arie Zask, Vincent P. Sandanayaka, Mila T. Du, Jannie L. Baker
  • Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
    Patent number: 6340691
    Abstract: Compounds of the formula are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: January 22, 2002
    Assignee: American Cyanamid Company
    Inventors: Jeremy I. Levin, Aranapakam M. Venkatesan, Derek C. Cole, James M. Chen, Jamie M. Davis, George T. Grosu
  • Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
    Publication number: 20010056088
    Abstract: Hydroxamic acids having the formula 1
    Type: Application
    Filed: June 14, 2001
    Publication date: December 27, 2001
    Applicant: American Cyanamid Company
    Inventors: Jeremy I. Levin, James M. Chen
  • Acetylenic &bgr;-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
    Patent number: 6326516
    Abstract: The invention discloses hydroxamide acids of the formula: which are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: December 4, 2001
    Assignee: American Cyanamid Company
    Inventors: Jeremy I. Levin, James M. Chen, Arie Zask
  • Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
    Publication number: 20010046989
    Abstract: This invention provides, low molecular weight, non-peptide inhibitors of matrix metalloproteinases and TNF-&agr; converting enzyme (TACE, tumor necrosis factor-&agr; converting enzyme) of formula:
    Type: Application
    Filed: December 11, 2000
    Publication date: November 29, 2001
    Inventors: Jeremy I. Levin, Arie Zask, Yansong Gu, Jay D. Albright, Xuemei Du
  • Acetylenic sulfonamide thiol tace inhibitors
    Patent number: 6313123
    Abstract: The compounds of formula B: which are useful in disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: November 6, 2001
    Assignee: American Cyanamid Company
    Inventors: Jeremy I. Levin, James M. Chen
  • Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
    Publication number: 20010025047
    Abstract: This invention provides, low molecular weight, non-peptide inhibitors of matrix metalloproteinases and TNF-&agr; converting enzyme (TACE, tumor necrosis factor-&agr; converting enzyme) of formula:
    Type: Application
    Filed: December 11, 2000
    Publication date: September 27, 2001
    Inventors: Jeremy I. Levin, Arie Zask, Yansong Gu, Jay D. Albright, Xuemei Du
  • Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
    Patent number: 6277885
    Abstract: Hydroxamic acids having the formula are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: August 21, 2001
    Assignee: American Cyanamid Company
    Inventors: Jeremy I. Levin, James M. Chen
  • Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
    Patent number: 6228869
    Abstract: This invention provides, low molecular weight, non-peptide inhibitors of matrix metalloproteinases and TNF-&agr; converting enzyme (TACE, tumor necrosis factor-&agr; converting enzyme) of formula: B wherein B is P and Q are provided that when P is Q is and vice versa; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 14, 1998
    Date of Patent: May 8, 2001
    Assignee: American Cyanamid Company
    Inventors: Jeremy I. Levin, Arie Zask, Yansong Gu, Jay D. Albright, Xuemei Du
  • Acetylenic &agr;-amino acid-based sulfonamide hydroxamic acid tace inhibitors
    Patent number: 6225311
    Abstract: Compounds of the formula: are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: May 1, 2001
    Assignee: American Cyanamid Company
    Inventors: Jeremy I. Levin, James M. Chen, Derek C. Cole, Mila T. Du, Leif M. Laakso
  • Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
    Patent number: 6200996
    Abstract: Compounds of the formula: are useful in treating disease conditions mediated by TNF-&agr; such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: March 13, 2001
    Assignee: American Cyanamid Company
    Inventors: Jeremy I. Levin, James M. Chen, Frances C. Nelson
  • Method of treating or inhibiting neutropenia
    Patent number: 5932585
    Abstract: The invention is a method of treating or inhibiting neutropenia, or accelerating neutrophil recovery in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound having the formula: ##STR1## wherein R.sub.1 and R.sub.2 are each, independently selected from the group consisting of hydrogen, alkyl of 1-6 carbon atoms, optionally substituted benzoyl, ##STR2## or R.sub.1 and R.sub.2 are methylene groups which are taken together to form a 4-7 membered saturated heterocyclic ring;R is hydroxy, 4-morpholinyl, 1H-imidazol-1 -yl, --CH(alkoxy of 1-6 carbon atoms).sub.2, .alpha.-hydroxybenzyl, or optionally substituted phenyl;R.sub.3 is hydrogen or alkyl; R.sub.4 is hydrogen, halogen, alkyl, alkoxy, or trifluoromethyl; R.sub.5 is hydrogen or alkyl; and n=1-3, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 16, 1997
    Date of Patent: August 3, 1999
    Assignee: American Cyanamid Company
    Inventors: Joseph W. Epstein, Jeremy I. Levin, James J. Gibbons, Judy Lucas
  • Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
    Patent number: 5405849
    Abstract: Novel quinazolinone compounds of the formula: ##STR1## wherein R.sup.5, R.sup.6, R.sup.7, R.sup.8, R and X are defined in the specification, which have angiotensin II (AII) antagonizing activity, intermediates useful in the preparation of the compounds, methods of producing and using the compounds to alleviate angiotensin induced hypertension and treat congestive heart failure in mammals.
    Type: Grant
    Filed: October 29, 1993
    Date of Patent: April 11, 1995
    Assignee: American Cyanamid Company
    Inventors: Aranapakam M. Venkatesan, Jeremy I. Levin
  • Angiotensin II receptor blocking 2, 3, 6 substituted quinazolinones
    Patent number: 5358951
    Abstract: This disclosure describes novel 2,3,6, substituted quinazolinones of the formula: ##STR1## wherein R.sub.1, R.sup.6 and X are described in the specification which have activity as angiotensin II (AII) antagonistis.
    Type: Grant
    Filed: April 23, 1993
    Date of Patent: October 25, 1994
    Assignee: American Cyanamid Company
    Inventors: Jeremy I. Levin, Aranapakam M. Venkatesan
  • Expedient route to aryl propenoic esters
    Patent number: 5352820
    Abstract: The invention is an expedient route to synthesizing substituted or unsubstituted aryl-2-propenoic esters. The substituted or unsubstituted aryl-2-propenoic esters are useful in preparing optically active substituted or unsubstituted 2-arylpropanoic acids known to be active anti-inflammatory agents.
    Type: Grant
    Filed: June 28, 1993
    Date of Patent: October 4, 1994
    Inventor: Jeremy I. Levin
  • Angiotensin II receptor blocking 2,3,6-substituted quinazolinones
    Patent number: 5338736
    Abstract: This disclosure describes novel 2,3,6-substituted quinazolinones of the formula: ##STR1## where R.sup.6, R.sup.5 and R are described in the specification which have activity as angiotensin II (AII) antagonists.
    Type: Grant
    Filed: October 7, 1993
    Date of Patent: August 16, 1994
    Assignee: American Cyanamid Company
    Inventor: Jeremy I. Levin